Invokana (canagliflozin) Invokana (canagliflozin), an SGLT2 inhibitor, is now a first-line option for Type 2 diabetes patients with cardiovascular disease, high cardiovascular risk, heart failure, or chronic kidney disease (CKD), regardless of baseline A1C, according to the 2022 American Diabetes Association (ADA) Standards of Care in Diabetes
The specific protocol used in any individual case depends on the patient's clinical picture and is determined by the provider
The peptide diffuses into the damaged area where it stimulates collagen synthesis and attracts healing cells
For instance, Novo Nordisk is seeking to enroll 2,500 people for a study of how its brand-name GLP-1 medication, Wegovy, is being used in the real world
To get the most benefit from GLP-1 medications and manage side effects effectively, it is best to combine them with an intentional diet, regular exercise, and mindful habits
STEP 3 Maintain Your Weight Loss - The Right Way
